share_log

Chardan Capital Downgrades Editas Medicine to Neutral

Benzinga ·  Dec 13 22:25

Chardan Capital analyst Geulah Livshits downgrades Editas Medicine (NASDAQ:EDIT) from Buy to Neutral.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment